Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | TP53 |
Variant | exon5 |
Impact List | unknown |
Protein Effect | unknown |
Gene Variant Descriptions | TP53 exon 5 indicates an unspecified mutation has occurred in exon 5 of the TP53 gene. |
Associated Drug Resistance | |
Category Variants Paths |
TP53 mutant TP53 exon5 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03940352 | Phase I | Siremadlin + Venetoclax Sabatolimab + Siremadlin | HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) | Terminated | USA | ITA | FIN | ESP | DEU | AUS | 1 |
NCT03641313 | Phase II | Berzosertib + Irinotecan | Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer | Active, not recruiting | USA | 0 |